Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma (Q34568471)

3 August 2017

Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. (English)

1 reference

3 August 2017

0 references

1 reference

Cristina R Ferrone

1

1 reference

3 August 2017

Dianne M Finkelstein

2

1 reference

3 August 2017

Sarah P Thayer

3

1 reference

3 August 2017

Alona Muzikansky

4

1 reference

3 August 2017

Carlos Fernandez-delCastillo

5

1 reference

3 August 2017

Andrew L Warshaw

6

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

Journal of Clinical Oncology

3 August 2017

1 reference

3 August 2017

24

1 reference

3 August 2017

18

1 reference

3 August 2017

2897-2902

1 reference

Usefulness of novel tumour markers

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3817569

Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3817569

Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3817569

Specific Antigen in Serum of Patients with Colon Carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3817569

Colorectal carcinoma antigens detected by hybridoma antibodies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3817569

Utility of tumor markers in determining resectability of pancreatic cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3817569

CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3817569

Clinical usefulness of CA-19-9 in pancreatic carcinoma

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3817569

Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin

27 October 2018

1 reference

12 December 2020

Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma

1 reference

12 December 2020

Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9

1 reference

12 December 2020

CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer

1 reference

12 December 2020

CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin

1 reference

12 December 2020

Prognostic value of CA 19-9 serum course in pancreatic cancer

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2005.05.3934

1 reference

3 August 2017

1 reference

3 August 2017

1 reference